Nevertheless, extrapolating from the adjuvant TKI trials in EGFR/ALK subsets and the evidence that immunotherapy confers minimal benefit in the metastatic setting, the use of adjuvant anti-PD(L)1 ICI is not favored for resected ROS1+ NSCLC.92 Understanding the efficacy and long-term tolerability of next-generation ROS1 TKIs will help inform their optimal placement in the non–metastatic treatment landscape. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.